BioSpace News Archive

Clear Creek Bio, Inc. announced today that the company has received U.S. Food and Drug Administration (FDA) clearance on an Investigational New Drug (IND) application for brequinar for the treatment of COVID-19 and has dosed the first patient in a Phase 1 clinical study.

When girls reach puberty at an unusually early age, they face a significantly higher risk of developing breast cancer later in life. Now, experts at Cincinnati Children’s and the University of Cincinnati offer a new, unified explanation for why that increased risk occurs.

Vivos Inc (OTCQB:RDGL), a company that has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals and in humans, today announced that it will be presenting at the LD 500 investor conference on Thursday September 3 at 1:40 PST / 4:00 PM EST.

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval of its MiniMed™ 770G hybrid closed loop system.

Real Time Medical Systems (Real Time), today announced the launch of its new Infection Control and Antibiotic Stewardship Surveillance solution, a live analysis and patient surveillance solution for Infection Preventionists (IPs) and clinical teams to manage the spread of infectious diseases and reduce antibiotic-resistance cases.

Patients traditionally rely on hospital comparison charts and rating systems for guidance on quality care, but hospital ratings specific to orthopaedic surgery can be misleading due to a lack of stated methodology, according to research published in the Journal of the American Academy of Orthopaedic Surgeons this month.

Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced t

Mesara will guide communications and marketing strategy for the independent biomedical research and treatment center

MDLand, the leading EHR solution, population health management and digital health platform company in New York City for many primary care practices, announced today that they have selected the Link+ by LiveCare as the premier devices for their Remote Patient Monitoring (RPM) solutions servicing their chronic care patients and population health management.

LUCA Science, a company developing functional mitochondria as therapeutic agents, an emerging platform to treat damaged tissues and organs, today announced the closing of a $9.8 million Series A financing. The funding round was led by Axil Capital Partners. Additional participating investors included Remiges Ventures, Nippon Venture Capital, Fast Track Initiative and CaHC. This press release features multimedia. View the full r